Klinische studies chronisch lymfatische leukemie (CLL)

Onbehandelde patiënten

LOXO BTX-20030

A phase 3 open label randomized study of pirtobrutinib versus Ibrutinib in patients with CLL / SLL: PART 2 evaluates pirtobrutinib mono in treatment naïve CLL/SLL with 17p deletions

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT05254743
• Internal reference number: S66576

BELLWAVE-011 (MK1026-011-00)

A Phase 3, Randomized Study to Compare Nemtabrutinib Versus Comparator (Investigator’s Choice of Ibrutinib or Acalabrutinib) in Participants With Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06136559
• Internal reference number: S68241

HOVON 507 (CLL18)

A phase 3 multicenter, randomised, prospective, open-label trial of fixed-duration (12 cycles) venetoclax/ obinutuzumab vs. fixed-duration (15 cycles) venetoclax/ pirtobrutinib vs. MRD-guided venetoclax/ pirtobrutinib in patients with previously untreated CLL/SLL aiming to establish measurement of individual residual disease for adjustment of treatment duration to improve outcomes.

• Principal investigator: Prof. Dr. Ann Janssens
• More information: HOVON 507 CLL / CLL18
• Internal reference number: S69659

Behandelde patiënten

HOVON 159

A prospective, multicenter, phase-II trial of venetoclax plus acalabrutinib in patients who have relapsed after first line venetoclax + anti-CD20 mAb treatment for chronic lymphocytic leukemia (CLL or SLL)

• Principal investigator: Prof. Dr. Ann Janssens
• More information: HOVON 159
• Internal reference number: S64626

BELLWAVE-010 (MK1026-010)

A Phase 3, open-label, randomized study to compare the efficacy and safety of Nemtabrutinib (MK-1026) plus Venetcolax Versus Venetoclax plus Rituximab in participants with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma following at least 1 prior therapy – PART 1B

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT05947851
• Internal reference number: S67497

J2N-MC-JZNX

A phase 2, open label, randomized study evaluating the efficacy and safety of 3 doses of pirtobrutinib in participants with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who previously received treatment with a covalent bruton tyrosine kinase inhibitor.

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06588478
• Internal reference number: S69650

GLORA (APG2575CG301)

A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Lisaftoclax (APG-2575) in Previously Treated Patients with CLL/SLL

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06104566
• Internal reference number: S68713

BGB-11417-303CLL

A Phase 3 Randomized, Open-Label, Multicenter Study of Sonrotoclax Plus Anti-CD20 Antibody Therapies Versus Venetoclax Plus Rituximab in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

• Principal investigator: Prof. Dr. Ann Janssens
• More information: NCT06943872
• Internal reference number: S70707